News

Kuter discusses the efficacy and safety of rilzabrutinib in sustaining platelet responses and symptom improvement over the LUNA3 long-term extension.

Investigators compared the 2-year drug survival rates of biologics and JAKi in atopic dermatitis, in addition to evaluating associated predictors.

Phase 2b REZOLVE-AD trial data show rezpegaldesleukin improves skin symptoms and asthma control in adults with moderate-to-severe atopic dermatitis.

Stay updated with the latest healthcare breakthroughs, including several new FDA approvals, in this week's essential news roundup.

The FDA has approved etripamil nasal spray for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia to sinus rhythm.

In this survey, investigators evaluated patients’ comprehension of frequently used cutaneous oncology-related words and looked at factors impacting their comprehension.

Cross-sectional analysis from NHANES shows patients with advanced cardiovascular-kidney-metabolic syndrome are at an increased sarcopenia risk.

FDA approves zoliflodacin (Nuzolvence) for uncomplicated gonorrhea, offering a new oral treatment amid rising antibiotic resistance.

Jain describes the phase 3 WIL-33 trial, which marked the first test of pdVWF/FVIII in adolescent patients aged <6 years.

Berotralstat (ORLADEYO) oral pellets become the first FDA-approved therapy specifically designed to prevent HAE attacks in children aged 2 – 11 years.

The approval of a dye- and preservative-free powder formulation of trofinetide offers a new option for adult and pediatric patients with Rett syndrome.

The phase 3 DISCREET study explored the safety and efficacy of apremilast in treating patients with moderate to severe genital psoriasis over 32 weeks.

2025 data show the US is still failing to adequately identify and initiate care for deadly lung disease. Experts discuss what it will take to turn the tide on this public health issue.

Weight-adjusted waist index outperforms obesity indices for cardiovascular disease prediction in cardiovascular-kidney-metabolic syndrome

Historic progress in renal xenotransplantation in 2025 brings pig kidney transplants closer to clinical reality amid an ongoing donor organ shortage.

The FDA has announced a proposal to include bemitrizinol to its list of allowable active ingredients to include in sunscreens.

A 20-year population study found unilateral adrenalectomy raises long-term risks of CKD and gout in primary aldosteronism.

This approval of GSK plc’s gepotidacin as an oral option for patients with uncomplicated urogenital gonorrhea follows EAGLE-1 phase 3 trial findings.

Findings comparing kidney-after-liver to simultaneous transplant highlight similarities in allograft survival outcomes, but notable eGFR differences.

Singhal reviews new AGA survey data on public perceptions of obesity as a chronic disease and describes opportunities to improve care.

Veeral Sheth, MD, is joined by the senior vice president of sales and marketing at Nanoscope Therapeutics to discuss the company's trajectory and the MCO-010 program.

A prediction model ties emergency visits and opioid doses with return visits in children with sickle cell disease pain.

In this interview, Serrao discusses the significance of the phase 2 INTEGUMENT-INFANT study, assessing once-daily roflumilast (Zoryve) cream 0.05% in infants with atopic dermatitis.

Cohran describes her research on characteristics linked to treatment response to teduglutide for short bowel syndrome-associated intestinal failure.

Reau and Brown discuss the recent CDC APIC decision to remove the universal birth-dose hepatitis B vaccine for infants born to mothers who test negative for HBV.

From diagnosis, investigators sought to explore psoriasis characteristics, patient demographics, patterns of treatment, and disease progression.

Zackon discusses a retrospective 20-year analysis, which implies an easier-to-achieve hemoglobin target in myelodysplastic syndrome treatment.